Lombard Odier Asset Management (Switzerland)’s Allogene Therapeutics ALLO Stock Holding History

Lombard Odier Asset Management (Switzerland)’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-258,214	Closed	-$2.79M	–	360
2022 Q3	$2.79M	Sell	258,214 -47,039	-15%	-$639K	0.24%	97
2022 Q2	$3.48M	Sell	305,253 -195,966	-39%	-$1.74M	0.29%	80
2022 Q1	$4.57M	Sell	501,219 -494,897	-50%	-$5.15M	0.36%	64
2021 Q4	$14.9M	Buy	996,116 +81,700	+9%	+$1.44M	0.95%	39
2021 Q3	$23.5M	Buy	914,416 +140,854	+18%	+$3.34M	1.46%	26
2021 Q2	$20.2M	Buy	773,562 +236,824	+44%	+$6.75M	1.02%	43
2021 Q1	$18.9M	Buy	+536,738	New	+$18.1M	1.26%	26

Other funds holding ALLO

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Lombard Odier Asset Management (Switzerland)'s ALLO Position: Q4 2022 in Review

Lombard Odier Asset Management (Switzerland) sold out of Allogene Therapeutics (ALLO) in Q4 2022, closing a stake of 258,214 shares — an estimated $2.79M sold.

Lombard Odier Asset Management (Switzerland) first reported a position in ALLO in Q1 2021 and held it in 7 quarters. The position peaked at $23.5M in Q3 2021. 168 funds tracked by Wall St. Rank hold ALLO as of Q4 2022.

Lombard Odier Asset Management (Switzerland) reported no remaining Allogene Therapeutics position as of Q4 2022 after selling out during the quarter.
Lombard Odier Asset Management (Switzerland) sold 258,214 Allogene Therapeutics shares in Q4 2022, an estimated $2.79M.
Lombard Odier Asset Management (Switzerland) first reported a position in Allogene Therapeutics in Q1 2021 and held it in 7 quarters.
Lombard Odier Asset Management (Switzerland)'s Allogene Therapeutics position peaked at $23.5M in Q3 2021.
168 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2022.

Based on Lombard Odier Asset Management (Switzerland)'s 13F filing for Q4 2022, filed 14 Feb 2023.